Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
Acumen Pharmaceuticals (NASDAQ: ABOS) has announced its participation in the upcoming Stifel Healthcare Conference. The company's management will engage in a fireside chat on Monday, Nov. 18, 2024, at 11:30 a.m. ET. Acumen, a clinical-stage biopharmaceutical company, is developing a novel treatment targeting toxic soluble amyloid beta oligomers for Alzheimer's disease. The presentation will be accessible via live webcast on the company's website under the Investors tab and will remain available for 90 days following the event.
Acumen Pharmaceuticals (NASDAQ: ABOS) ha annunciato la sua partecipazione alla prossima Stifel Healthcare Conference. Il management dell'azienda parteciperà a una discussione informale lunedì 18 novembre 2024, alle 11:30 ET. Acumen, un'azienda biofarmaceutica in fase clinica, sta sviluppando un nuovo trattamento mirato a oligomeri tossici di amiloide beta solubili per l'Alzheimer. La presentazione sarà accessibile tramite webcast dal vivo sul sito web dell'azienda sotto la sezione Investitori e rimarrà disponibile per 90 giorni dopo l'evento.
Acumen Pharmaceuticals (NASDAQ: ABOS) ha anunciado su participación en la próxima Stifel Healthcare Conference. La dirección de la empresa participará en una charla informal el lunes, 18 de noviembre de 2024, a las 11:30 a.m. ET. Acumen, una empresa biofarmacéutica en etapa clínica, está desarrollando un nuevo tratamiento dirigido a oligómeros de amiloide beta solubles tóxicos para la enfermedad de Alzheimer. La presentación estará disponible a través de una transmisión web en vivo en el sitio web de la empresa en la pestaña de Inversores y permanecerá accesible durante 90 días después del evento.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 다가오는 Stifel Healthcare Conference에 참가한다고 발표했습니다. 회사 경영진은 2024년 11월 18일 월요일 오전 11시 30분 ET에 파이어사이드 채팅에 참여할 예정입니다. Acumen은 임상 단계의 생물의약품 회사로, 알츠하이머병을 위한 유독한 수용성 아밀로이드 베타 올리고머를 겨냥한 새로운 치료법을 개발하고 있습니다. 발표는 회사 웹사이트의 투자자 탭을 통해 생중계로 시청할 수 있으며, 이벤트 후 90일 동안 제공됩니다.
Acumen Pharmaceuticals (NASDAQ: ABOS) a annoncé sa participation à la prochaine Stifel Healthcare Conference. La direction de l'entreprise participera à une discussion informelle le lundi 18 novembre 2024, à 11h30, heure de l'Est. Acumen, une entreprise biopharmaceutique en phase clinique, développe un nouveau traitement ciblant les oligomères d'amiloïde bêta solubles toxiques pour la maladie d'Alzheimer. La présentation sera accessible en direct sur le site web de l'entreprise dans l'onglet Investisseurs et restera disponible pendant 90 jours suivant l'événement.
Acumen Pharmaceuticals (NASDAQ: ABOS) hat seine Teilnahme an der bevorstehenden Stifel Healthcare Conference angekündigt. Die Unternehmensleitung wird am Montag, den 18. November 2024, um 11:30 Uhr ET an einem Fireside-Chat teilnehmen. Acumen, ein Unternehmen in der klinischen Entwicklungsphase für biopharmazeutische Produkte, entwickelt eine neuartige Therapie, die auf toxische lösliche Amyloid-Beta-Oligomere für Alzheimer abzielt. Die Präsentation wird über einen Live-Stream auf der Website des Unternehmens unter dem Reiter Investoren zugänglich sein und bleibt 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET.
The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (ABOS) presenting at the Stifel Healthcare Conference 2024?
How can I watch Acumen Pharmaceuticals' (ABOS) Stifel Healthcare Conference presentation?
What type of treatment is Acumen Pharmaceuticals (ABOS) developing?
What format will Acumen Pharmaceuticals' (ABOS) presentation take at the Stifel Conference?
